-
Mashup Score: 26Association of Sacubitril/Valsartan vs Valsartan With Blood Pressure Changes and Symptomatic Hypotension: the PARAGLIDE-HF Trial - 17 hour(s) ago
In PARAGLIDE-HF, in patients with ejection fraction (EF) > 40%, stabilized after worsening heart failure (WHF), sacubitril/valsartan led to greater reduction in plasma NT-proBNP levels and was associated with clinical benefit compared to valsartan alone, despite more symptomatic hypotension (SH). Concern about SH may be limiting the use of sacubitril/valsartan in appropriate patients.
Source: onlinejcf.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2
The trial, as well as pooled data with PARAGON-HF, should solidify a role for sacubitril/valsartan after worsening HF events.
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet-
More #ARNI Insights Fortify Role in ‘Below Normal’ #LVEF: #PARAGLIDE-HF The trial, as well as pooled data with #PARAGON-HF, should solidify a role for sacubitril/valsartan after worsening HF events @TCTMD @ShelleyWood2 @mmamas1973 #HeartFailure2023 https://t.co/CcMUGMzrdt
-
Which patients with HFmrEF/HFpEF are most likely to develop symptomatic hypotension with ARNI? Risk factors from #PARAGLIDE-HF Trial: ⚪️ LVEF > 60% ⚪️ SBP < 128 mmHg ⚪️ White race ARNI benefit may be greatest in pts with LVEF < 60% and higher SBP 🔗https://t.co/ZE4V0LfVr1 https://t.co/n47hij2R4Q